Luc-Matthieu Fornecker, MD, PhD: Risks and Benefits of BV + AVD in Treatment-Naive Hodgkin...
In the multicenter BREACH trial, adding brentuximab vedotin to AVD chemotherapy in patients with unfavorable, early-stage Hodgkin lymphoma led to higher rates of PET...
Prithviraj Bose, MD: Optimizing Ruxolitinib With Sotatercept for Myelofibrosis
Dr. Bose discusses updated results from a phase II trial of sotatercept alone and with ruxolitinib, the only FDA-approved therapy for myelofibrosis, which also...
Jeanette K. Doorduijn, MD, PhD, and Samar Issa, MD: Does Rituximab Improve Survival in...
Results from a randomized phase III trial examining rituximab in patients with central nervous lymphoma show that treatment with rituximab does not improve response...
James N. Kochenderfer, MD: Advancing CAR T-Cell Therapy for Myeloma
Dr. Kochenderfer reports "very exciting" results from bb121, a new BCMA-targeting CAR T-cell therapy for treating patients with heavily pretreated myeloma, trending towards less...
Yazan F. Madanat, MD: How Does Smoking Increase MDS Risk?
Smoking is associated with an increased risk of developing mutations that lead to myelodysplastic syndromes, but the association changes with patients' smoking patterns. Dr....
Stephen J. Schuster, MD: Tisagenlecleucel Promising in Relapsed/Refractory DLBCL
Dr. Schuster shares results from the global JULIET trial of the CAR T-cell therapy tisagenlecleucel in patients with relapsed/refractory diffuse large B-cell lymphoma -...
Joseph Connors, MD: Bleomycin or Brentuximab Vedotin in Hodgkin Lymphoma?
Replacing bleomycin with brentuximab vedotin in standard ABVD therapy led to a "modest improvement" in outcomes for patients with Hodgkin lymphoma, without increased long-term...
Geoffrey L. Uy, MD: Investigating Flotetuzumab in AML and MDS
Dr. Uy discusses preliminary results from a phase I trial of flotetuzumab, a CD123 x CD3 bispecific DART protein, in patients with relapsed/refractory acute...
Gerald A. Soff, MD: Examining a New Indication for Romiplostim
Dr. Soff discusses results from a phase II study of romiplostim in treating patients with chemotherapy-induced thrombocytopenia. The agent led to high rates of...
Remco Molenaar, MD, PhD: TET2 Mutations Predict Cardiovascular Risk in MDS and CMML
Patients with myelodysplastic syndromes and chronic myelomonocytic leukemia and TET2 mutations have high risks of cardiovascular toxicity, suggesting that these patients might benefit from...
Current Issue
May 2018, Volume 4, Issue 6
This issue features a look at the hidden costs of importing lower-cost drugs, the optimal hemophilia treatment, the limits of genetic testing, and more.
